SBP GROUP 01177.HK Price

Sino Biopharmaceutical Limited (the "Company" or "Sino Biopharmaceutical") and its subsidiaries (the "Group") is a leading innovation and R&D-driven pharmaceutical group in China. Its business covers the entire industry chain, including pharmaceutical R&D platforms, intelligent manufacturing, and a strong sales system. Its products include a variety of biological and chemical drugs, and it holds a dominant position in four major therapeutic areas: oncology, liver diseases, respiratory system, and surgery/analgesia. The Company was listed on the Hong Kong Stock Exchange in 2000. In 2013, it was included as a constituent stock of the MSCI China Index under the MSCI Global Standard Indexes; in 2018, it was included as a constituent stock of the Hang Seng Index; in 2019, it was included as a constituent stock of the Hang Seng China Enterprises Index; in 2020, it was included as a constituent stock of the Hang Seng Stock Connect China BioTech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index. Sino Biopharmaceutical has been ranked among the "Top 50 Global Pharmaceutical Companies" published by the authoritative US magazine Pharm Exec for five consecutive years, and has been named one of the "Forbes Asia's 50 Best Companies in Asia-Pacific" for three consecutive years. The subsidiaries of Sino Biopharmaceutical are located in Beijing, Shanghai, Nanjing, Lianyungang and other places, with multiple pharmaceutical production bases. Since its establishment, the Company has continuously achieved outstanding results and steady development. Its core member companies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., have been listed among the Top 100 Chinese Pharmaceutical Industrial Enterprises for many years. The Company, with generics as its foundation, is undergoing a comprehensive transformation towards innovation. Innovative drugs drive growth, and their revenue share is increasing year by year. The internal R&D pipeline drives the innovation transformation, continuously upgrading the technology platform. Under the leadership of top scientific teams, it actively promotes internationalization and seizes frontier opportunities in the international arena. Sino Biopharmaceutical will uphold the mission of "Health Technology, Warming More Lives", focus on innovation, serve patients, and strive to become a globally leading pharmaceutical enterprise. We look forward to sharing the achievements of the pharmaceutical and healthcare industry with like-minded individuals, cooperating vigorously, and creating a win-win future! The Group's major subsidiaries include Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("Chia Tai Tianqing"), Beijing Tide Pharmaceutical Co., Ltd. ("Beijing Tide"), Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("Nanjing Chia Tai Tianqing"), Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. ("Jiangsu Chia Tai Fenghai"), Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. ("Jiangsu Chia Tai Qingjiang"), and invoX Pharma Limited ("invoX"). Nanjing Chia Tai Tianqing, Jiangsu Chia Tai Qingjiang, and Jiangsu Chia Tai Fenghai have been respectively recognized by the Jiangsu Provincial Department of Science and Technology as the "Jiangsu Engineering Technology Research Center for Anti-tumor and Cardiovascular/Cerebrovascular Plant Chemical Drug Preparations", "Engineering Technology Research Center for Orthopedic Drug Preparations", and "Engineering Technology Research Center for Parenteral Nutrition". The R&D center of Chia Tai Tianqing is a "Postdoctoral Research Station" granted by the Ministry of Human Resources and Social Security of China, and it is the only "Engineering Technology Research Center for Novel Liver Disease Drugs" in China. Beijing Tide received the GMP certification from the Japanese Ministry of Health, Labour and Welfare for foreign pharmaceutical enterprises again in December 2012. Japanese pharmaceutical companies can entrust Beijing Tide to produce and export sterile preparations of drugs under development or already marketed in Japan to Japan.